

Review Article

Current Perspectives on Tissue Engineering for the Management of Limbal Stem Cell Deficiency

Bakiah Shaharuddin^{1,2*} and Annette Meeson²¹Advanced Medical and Dental Institute, Universiti Sains Malaysia, Malaysia²Institute of Genetic Medicine, Faculty of Medical Sciences, Newcastle University, UK***Corresponding author:** Bakiah Shaharuddin, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, 13200 Pulau Pinang, Malaysia and Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle Upon-Tyne, NE1 3BZ, UK; Email: bakiah@usm.my**Received:** June 15, 2015; **Accepted:** October 01, 2015;**Published:** October 08, 2015**Abstract**

Limbal Stem Cell Deficiency (LSCD) encompasses a group of eye disorders characterized by abnormal maintenance of the limbal stem cells. This painful and potentially blinding condition poses a challenge in transplantation biology; whereby whole corneal transplantation would normally fail due to the depletion of the recipients' limbal stem cells. The most preferred technique of management is transplantation of *ex vivo* expanded limbal stem cells to the damaged eyes. This article discusses the therapy options for unilateral and bilateral cases of LSCD, the clinical outcomes, components of cells and substrates that are currently being investigated or have been utilized by this technique, and brings into focus the newer therapy of using a scaffold-free cell delivery system to treat LSCD.

Keywords: Limbal stem cells; Limbal stem cell deficiency; Tissue engineering; Cell sheet**Abbreviations**

AM: Amniotic Membrane; BM: Bone Marrow; EGF: Epidermal Growth Factor; ECM: Extracellular Matrix; ESC: Embryonic Stem Cells; GMP: Good Manufacturing Practice; iPSC: induced Pluripotent Stem Cells; LEC: Limbal Epithelial Cells; LSC: Limbal Stem Cells; LSCD: LSC Deficiency; MSC: Mesenchymal Stem Cells; PIPAAm: Poly N-Isopropylacrylamide; 3D: Three Dimensional

Introduction

The corneal limbus forms the narrow transition zone between the corneal and conjunctival epithelia and is believed to harbour the cornea stem cells [1-3]. The limbal stroma is an area rich in blood vessels, contains melanocytes, Langerhans cells and abundant with nerve supply. Adult stem cells are now believed to reside in most tissue populations for regenerative purposes and tissue repair. Stem cells are protected from hostile external factors in a specialized microenvironment called the "stem cell niche". It is hypothesized that the stem cells for the cornea are deposited deep in the basal layer of the limbus [3-7].

More recent advances using the lineage tracing technique in K14+ve Confetti mice supported the evidence that mouse limbus significantly contributed to self renewal and regeneration of the mouse cornea [8,9]. Limbal cells also responded rapidly to major wounding compared to the wound healing potential of the long-term corneal clones which mainly responded to minor injury [9].

Limbal Stem Cell Deficiency (LSCD)

This is a painful and blinding condition of the eye caused by abnormal maintenance of the LSC [10]. It can be broadly categorized into unilateral or bilateral involvement, acute or chronic conditions. Among the causes are hereditary genetic disorders called aniridia, where there is developmental dysgenesis of the anterior chamber of the eye due to PAX6 gene mutation [11,12]. Acquired causes of LSCD include chemical and thermal injury, inflammatory conditions

i.e Steven-Johnson syndrome, ocular cicatricial pterygium and chronic limbitis. Trauma, surgery and cryotherapy to the limbus, radiation and topical instillation or subconjunctival injection of toxic drugs are some iatrogenic causes.

In the majority of cases involving corneal blindness, whole corneal transplantation is the therapy of choice; but this is not the solution for LSCD. Failure of transplantation in this condition lies in the loss of host stem cells and thus, inadequate self renewing cells to replenish the epithelial surface of the grafts taken from the donor. Due to this, the management of LSCD shifts to transplantation of healthy limbal tissue to the damaged limbal areas. This follows the rationale that re-epithelisation will take place when there are residual healthy limbal cells in the diseased eye, or a sufficient number of limbal cells are replaced by transplanting whole pieces of healthy limbal tissues [13]. However, this surgical method will usually involve a large area of graft taken from a donor site, thus rendering it susceptible to secondary LSCD.

Current Perspective on Tissue Engineering for LSC Transplantation

Tissue engineering was first introduced as an interdisciplinary approach using cell biology and engineering to restore or enhance the biological functions of tissues and organs using substrates [14]. A landmark report in 1997 by Pellegrini revealed a successful transplantation of *ex vivo* expanded limbal epithelium grown on a fibrin carrier [15]. Another commonly used substrate is the amniotic membrane [16]. The outgrowths from the explants originated from a contra lateral healthy eye were allowed to proliferate to form a cell sheet before transplantation to the damaged eye. The advantage of using autologous *ex vivo* expansion of limbal epithelium is the small sized-biopsy taken from the healthy eye which will prevent secondary LSCD in the donor eye. The need for a long term immune suppression is usually eliminated [17]. These bioengineered tissue constructs comprising of a cellular component and a substrate counterpart allow the cells to grow and differentiate towards corneal epithelial

lineage and proliferate to form an epithelial sheet to be transplanted to the ocular surface. The purpose of this is to maintain the corneal epithelial barrier function from external insults such as pathogens, allergens, desiccation or mechanical injury.

Clinical Trials for Limbal Stem Cells Transplantation

Translational research involving *ex vivo* expansion of LSC and transplantation to treat LSCD was among the first stem cell tools to reach the patients. Using keywords such “limbal stem cell deficiency” and “limbal stem cell insufficiency” in a search at the database for human clinical trials <https://clinicaltrials.gov>, we found only 10 registered clinical trials (one trial on the use of collagenase in a tissue culture protocol was disregarded). These clinical trials mainly covered the use of established protocols for *ex vivo* expanded LSC and oral mucosa. This implies that the growing numbers of clinical studies for the treatment of LSCD remains in the academic institutions and laboratories; needing further optimization of protocols before materializing into registered clinical trials. Furthermore, the long and complex pathways from preclinical trials to regulatory approval and consent, Good Manufacturing Practice (GMP)-compliant laboratory protocols and industrial partnership for funding of clinical trials and production of “accredited tissues” are among the obstacles from making these studies nearer to the clinic [18,19]. Till date, Holoclar is the only *ex-vivo* expanded autologous human corneal epithelial stem cell product authorized to be used as an advanced therapy recommended by The European Medicines Agency (EMA) for the treatment of LSCD in the European Union. However, Holoclar still awaits comprehensive data report before being adapted for general clinical practice.

The Outcome of Ex Vivo Expanded Limbal Epithelial Transplantation

Several investigators have investigated into LSC fate and how restoration of the damaged ocular surface takes place after LSC transplantation [20]. It is very unlikely that it is due to replacement of stem cell numbers alone. It was suggested that LSC transplantation has stimulated dormant LSC to renew and proliferate to the site of injury. In addition, LSC transplantation was also believed to attract circulating corneal progenitors or directly from Bone Marrow (BM) to repopulate the site of injured ocular surface by a chemotactic stimulus. Studying the LSC fate in different aetiologies of stem cell deficiency and the types of tissue transplantation would be a future direction to explain the process of cellular restoration. At present, there is no consensus on LSC fate in different types of transplantation [20-22] such as in penetrating keratoplasty, alone or in combination with limbal allograft transplantation, or in the case of *ex vivo* LSC transplantation.

A short term review of 28 clinical studies on cultivated corneal epithelial transplantation since 1997 to 2010 shows a success rate of 67% [23]. This would probably be due to the majority of tissues used in these studies being autologous in nature (84%). Another long term study on the outcome of cultured limbal epithelial transplantation using fibrin as a carrier gave 66% of full success, 19% for partial success and 15% of failure rate respectively [24]. In another review of clinical outcomes [25], despite the heterogeneity of the type of grafts, the biological carrier to transplant LSC, culture methods, and

the clinical cause of the disease, the overall outcome of 17 studies was similar at 67% success rate. In a recent systematic review and meta-analysis of LSC transplantation using AM, an almost similar outcome was recorded. The success rate and vision improvement was at 67% and 62% respectively [26]. Surprisingly, there was no significant difference between autografts and allografts. A longer post transplantation period of observation is warranted to justify this conclusion.

It could not be emphasized enough that long term success of LSC transplantation depends on the quality of the grafts or the frequency of LSC on the grafts [27]. Rama et al, observed the presence of more than 3% of p63+ve stained cells in the holoclones were associated with 78% of success rate. The outcome could be improved by a more effective identification or isolation of LSC, or the use of stem cell enrichment methods such as the side population assay [28,29].

Similar to the allogeneic response occurring in solid organ transplantations, the issue with allogeneic tissue or cell transplants in LSC remains their immunogenicity due to major histocompatibility complex mismatch [30]. Major allogeneic responses include the “graft-versus-host” immunological reactions which need tolerance-inducing strategies [31,32].

In the case of total and bilateral LSCD, cultivated oral mucosa epithelial transplantation on AM has also been clinically applied with promising results [33,34]. This approach when reviewed for 15 treated eyes showed a success rate of 67% total re-epithelisation, without any major complications for a period of at least 34 months. A similar method, but in the absence of 3T3 feeders and animal serum has also been trialled in two patients with successful regeneration of corneal epithelium [35]. However, the phenotypic difference in the corneal and oral mucosa epithelia leads to new vascular formation and corneal opacity. A secondary penetrating keratoplasty may sometimes be performed to achieve a clear central cornea and improve visual acuity [36,37].

Alternative Sources of Cells

The lack of donor corneas in sufficient quantity and of sufficient quality to generate limbal epithelia for transplantation has motivated many clinicians and scientists to search for alternative sources of cells for cellular therapy. The option for replacement of adult limbal epithelial stem cells sourced from outside the cornea includes human Embryonic Stem Cells (ESC) which can be directed to the corneal epithelial lineage. Although ESCs have better differentiation and expansion potential than adult stem cells their use is hampered by ethical issues, regulatory problems and associated funding limitations.

The use of appropriate ECM cellular matrix i.e. collagen IV, laminin or fibronectin in a differential protocol successfully direct human ESC into corneal epithelia [38]. In a mouse derived ESC, the use of collagen IV as a culture substrate has resulted in corneal progenitors which expressed PAX6 and CK12 genes. PAX6 is important for ocular development while CK12 has been regarded as a specific marker of corneal epithelial differentiation. Indeed, transplantation of these corneal progenitors on denuded cornea produced epithelial surface re-epithelisation after 24 hours. However, restrictions surrounding ESC, namely ethical issues, technique of differentiation, accessibility and the costs, have limited the use of

ESC for a larger scale translational approach. Presence of human leucocyte antigen Class I molecules which are a major immunological mediators pose as an immunogenic challenge which requires tissue tolerance mechanisms before ESC transplantation [39,40].

In the meantime, the advent of human induced Pluripotent Stem Cells (iPSC) has partly resolved the ethical issues surrounding ESC. The use of transcription factors; Oct3/4, Sox2, c-Myc and Klf4 [41], on somatic cells can induce pluripotency in these cells, a process called “reprogramming”. Hayashi et al. successfully induced cornea epithelial cells from human adult dermal fibroblast-derived iPSC and human adult corneal limbal-derived iPSC [42] by using the stromal cell-derived inducing activity method. In an animal model, mouse iPSC had been demonstrated to differentiate into corneal epithelial-like cells when co-cultured with corneal stromal cells in the presence of additional factors such as β -Fetal growth factor, Epidermal Growth Factor (EGF) and nerve growth factor [43]. Transcriptionally induced pluripotent cells could be a source of tumour formation [44,45] due to lentiviral integration at the site of gene promoters, and poses the problem of a reliable cellular differentiation. There is also a concern about immunogenicity when used in transplantation [46]. The latter is reported to be related to aberrant methylation and epigenetic memory to their tissue of origin and dependent on the reprogramming methods.

MSCs have tri-lineage potential into adaptogenic, chondrogenic and osteogenic differentiation, have paracrine secretions of immunomodulatory molecules and immune-suppressive properties; ideal for cell-based therapeutic potentials. MSCs were originally isolated from BM, are conveniently isolated from other non-marrow tissue sources such as from the musculoskeletal system [47], adipose tissue [48], oral tissues [49] and umbilical cord blood [50]. Most studies utilizing MSC for LSCD were conducted in animals [51-53]. Almaliotis et al. recently used injectable MSC into the corneal stroma and conjunctiva of alkaline-induced injury in rabbits with a remarkable outcome [54]. Comparative studies between BM-derived and LSC showed comparable results for ocular surface regeneration in a rabbit model [48]. Although MSC-based therapies for the treatment of LSCD are rapidly evolving, the field is in need of further knowledge on the mechanism of action, standardized culture protocols and human clinical trials.

Substrates for Cell-Based Therapy

The second major component in tissue engineering is the biomaterials used as the substrate or scaffolds for cell delivery. The initial focus was to replicate the physical and mechanical properties of the target tissues. Prospectively, more emphasis is being given to develop “biomimetic” substrates which integrate the substrates with the biological environment resembling closely the natural topography of the limbal epithelial crypts as the supportive Extra Cellular Matrix (ECM) [55]. An ideal carrier substrate has often been described to have not only optical clarity, but also able to withstand the culture conditions, flexible to the shape of the cornea and quite tough for surgical manipulation including the suturing.

Biological Substrates

Fibrin sheet

Historically, the use of biological substrates has been the strategy

for LSC transplantation when fibrin sheet was first utilized for this indication [15]. A mixture of fibrinogen and thrombin was placed on a plastic ring to allow a coagulation cascade. Primary limbal keratinocytes were grown on feeder layers on this fibrin sheet and the cell to matrix construct were then transplanted to patients’ eyes [56]. A clinical trial involving larger number of patients showed a success rate of 76.6% up to 10 years [27]. Fibrin gels are transparent, absorbable and easier to manipulate however, they present a risk of contamination [57] and cause LSC differentiation [58].

Human amniotic membrane

AM as part of the carrier system to transfer limbal epithelial sheets has been the substrate of choice to restore ocular surface disorders [59]. AM facilitates re-epithelisation and has been shown to have anti-inflammatory [60], anti-angiogenic [61,62], and anti-scarring properties [63]. To date, AM has been the most widely used substrate to deliver LSC to the ocular surface. Several modifications have been tried to provide different forms of AM to improve its quality as a carrier, including the use of denuded AM over an intact membrane [33].

The drawbacks of AM are the difficulty to sustain the donor supply and clinical variations in the tissues which might affect the growth conditions. The screening of AM for transmission of diseases is costly and ineffective because it does not totally rule out viral transmission. Additionally, the use of scaffolds or substrates as implants is associated with risk of surgical infections [64]. Hence, researchers have explored the potentials of other materials and used new strategies to develop synthetic tissue-engineered constructs to improve the outcome of LSC transplantation for ocular surface regeneration.

Contact Lens (CL)

Di Girolamo group introduced CL populated by cellular expansion of limbal/conjunctival explants using a xeno-free culture system for autologous transplantation in partial and total LSCD [65]. Sixteen eyes of patients with multiple aetiologies showed an impressive restoration of epithelium in 63% of cases at 2.5 years of follow up. This delivery method of cell-based therapy is attractive in many ways; it uses a regular CL which makes the cost relatively affordable, surgically it is easier to manipulate, and transparency is not a problem. However, the explants method is preferable to the cell suspension method where multiple limbal/conjunctival biopsies from different sites need to be harvested to obtain an adequate size of cell sheet due to poor proliferation of cells from the explants on CL.

Collagen

Collagen forms a major component of the cornea stroma and naturally remodelled by the host cells. Hydrated collagens (hydrogels) are biocompatible, inert, biodegradable and attractive to replace or to complement AM. Hydrogels are more structurally uniform and the physical and mechanical properties can be modified to suit cellular proliferation [66]. Hydrogels are made up of a 3D network of polymers and water, comprised of macro-molecules connected by electrostatic forces, hydrogen bond, or covalent links. As a scaffold, hydrogels can encapsulate cells and biomolecules as a cellular niche. However, the large composition of water weakens the scaffolds. Cross-linking of collagen with other substances improve the mechanical property of a scaffold [67] however this might alter cellular remodelling and

Table 1: Biomaterials used in corneal epithelial tissue engineering in the clinical studies for LSCD.

Materials	Advantages	Disadvantages
Human Amniotic membrane	Stimulates re-epithelisation, have anti-inflammatory, anti-angiogenic and anti-scarring properties	Semi-transparent, donor to donor variability in the quality of tissues, risk of disease transmission and limited strength
Fibrin sheet	Transparent, absorbable, elastic and easier to manipulate	Risk of contamination and cause early LSC differentiation
Collagen	Biocompatible, relatively cheap, less immunogenic	Collagen hydrogels are mechanically weak, early contraction and easily degraded
Plastically compressed collagen	Transparent, mechanically strong and shaped to the ocular surface. Biocompatible for epithelial growth and stratification	Standardization of methods to achieve desired collagen concentration and density/stiffness to cater to collagen biomimetic properties.
Silk fibroin	Biodegradable, and compatible with cellular growth and proliferation.	Cost of production of natural silk and potential triggering of inflammatory response.
Contact Lens (CL)	Mechanically strong, transparent and easy to handle. Multiple biopsies harvested and grow in cultures is advantageous for repeat procedures.	Synthetic CL may not be an effective biological substrate for cell-based expansion of limbal/conjunctival explants resulting in poor proliferation of cells and loss of SC.
Nanofibers	Three-dimensional structure of nanoscaffolds allows a large surface area and a conducive environment for cellular growth along the fibers.	Electrospinning fibers consisting of polymers and solvents could be toxic to the cells.
Keratin films	Modification to the structures can produce keratin films which are transparent, absorbable and easy for surgical handling. Cellular growth and proliferation are comparable to AM	Optimisation of the structures of keratin films imperative to achieve a biocompatible construct, better for suturing, non-toxic and non-immunogenic.

impairs the biomimetic property of the substrate [68]. Fibrin, collagen, plastically compressed and alginate hydrogels [69-71] are some of the examples used in clinical studies for LSCD treatment. The use of hydrogels for cellular-based therapies needs a continuous search for the ideal and optimum balance of the composition of the polymer materials i.e. water, ionic cross-linking, pores and permeation. These properties will determine cellular adhesion and the biocompatibility of the materials for tissue engraftment [72].

Plastic compressed collagen

Plastic compression is a technique used to extract water from a collagen hydrogel by downward absorption onto a filter paper [73]. This is performed to increase the mechanical strength of the hydrogels. Levis et al demonstrated scaffolds made of compressed collagen gel when compared to denuded AM to be a better biomimetic substrate for the growth of Limbal Epithelial Cells (LEC) [74]. This proved to be mechanically strong, thin and transparent. Additionally, these collagen can be further molded into 3D niche structure mimicking the limbal crypts to allow for better LSC growth [55]. However further standardization of the methods and clinical data is necessary before taking it further as a cell-based therapy for LSCD [75].

Nanofibers

Fabricated nanofibers can be produced by electro spinning methods where biocompatible substrates and polymers are interwoven together [76]. This three-dimensional structure allows a large surface area and a suitable environment for stem cells growth and transfer. In a recent study, fibrous nanoscaffolds from poly-ε-caprolactone demonstrated numerous advantageous properties of controlled shape and porosity, and have a high surface: volume ratio. As a 3D biocompatible structure, this can mimic the physiological ECM cellular matrix, used for synthetic ocular surface regeneration. This scaffold system was shown to be biocompatible with LEC and use of these with cells resulted in good cellular adhesion and cell proliferation [77]. A recent clinical study using MSCs seeded on nanofibers showed significant wound healing from alkaline injury with suppression of inflammation in a rabbit model [78].

Silk fibroin

A biodegradable material has the advantage of variable degradation rate for the viable cells to be released at the site of injury.

Silk fibroin which is synthesized from the cocoon of silkworm has been found to be a useful substrate for LEC; it was able to support corneal epithelial proliferation, differentiation and stratification [79,80], although induction of an inflammatory response in the host is a primary concern. The cost of production of a natural silk material for bioengineering is an area of concern. A combination of silk with synthetic materials such as polymers and ceramic for the purpose of cell-based therapy in the cornea is an interesting area for further investigations.

Keratin films

Keratins are a group of structural proteins present on the epithelia of hard or filamentous structures such as the hair, nails, feathers and hoofs of higher vertebrates. Keratin makes these structures to be water insoluble, however its mechanical strength and capability for cells to grow and proliferate on modified keratin-coated culture surfaces have garnered a lot of interest in tissue engineering. Reichl et al. demonstrated in vitro human corneal epithelial growth on modified keratin films that was comparable to AM [81]. By mixing two types of keratin dialysate and subjected it to multiple steps in processing, the keratin films that were produced were mechanically strong for surgical handling but encountered difficulty such as suture loosening; which needs further modification to the keratin structures.

There is an increasing need to develop a synthetic, biocompatible and slowly biodegradable material which could be used as substitute for the AM. The use of a synthetic material would lessen the risk of infection. A substrate which is resilient, biocompatible, and able to adapt to the surface of the eye is an ideal carrier system for delivering of cultured corneal epithelium and a viable option for cellular-based therapy. A summary of tissue-engineered substrates is provided in Table 1.

Emerging Techniques and Future Directions

Decellularised tissues

Strategies involving decellularisation of tissues and organs have been of interest to LSC biologists in the past decade. This technique involves complete removal of cellular components, cellular materials and antigens from tissues to reduce its immunogenicity [82]. This is done while maintaining the corneal structure and the ECM. Decellularisation can be achieved by using chemical and enzymatic

methods, followed by re-seeding with new cells, a process called “scaffold recellularisation” [83,84]. The challenge is to find the right seeding density and the choice of repopulating the surface or via injecting into the scaffold. Maintaining a close balance of preserving structural, mechanical and physiological properties of the decellularised cornea and reducing cellular immunogenicity are among the challenges in this area.

Cell sheet tissue-engineered system

A technique developed to escape from any use of carrier system is a new temperature-responsive polymer e.g. Poly N-isopropylacrylamide (PIPAAm) as a cell sheet engineering system introduced by Okano group and first used in the cornea by Nishida in 2004 [85]. This method allows transfer of cells and the ECM to the ocular surface at different temperature conditions in the absence of a scaffold. PIPAAm polymer and its co-polymer show a hydrophobic state at 37°C and at this temperature cells would adhere and proliferate. At 32°C and below, the cells are detached because of polymer hydration, which allows harvesting of the cells in a mono layer cell sheet while maintaining cell-to-cell and cell-to-ECM contact. Cell sheet fabricated hepatocytes and β -islet cells have been engineered for clinical treatment of liver failure and type I diabetes mellitus [86,87]. As for the treatment of cardiac diseases, a plethora of options are available from cardiomyocytes cell sheets, myoblast sheets, MSC sheets and cardiac progenitor cell sheets for cardiac regeneration [88].

Tissue-engineering in the cornea has often maintained the use of a carrier system for delivery of the cells. A carrier system has the disadvantages of an exposure to infections and transmission of pathogens, especially in the case of biological scaffolds. Both of these factors can hinder tissue integration and affect the survival of tissue transplantation. Suture less techniques as advocated in the transplantation of cell sheets also have the advantages of reducing inflammation post-operatively [85].

The cell sheet engineering system has expanded to include autologous oral mucosa cell sheet fabrication for the treatment of bilateral cases of LSCD; a potential alternative carrier to AM [89,90]. In a study of 26 eyes with bilateral LSCD, transplanted oral mucosa cell sheets supported successful regeneration of the ocular surface with 64% success rate, reduced vascularization and demonstrated a safe and well-tolerated product [90]. This suggests the therapy would also be beneficial for LSCD caused by ocular infection, aggressive surgery at the limbus, contact lens wear and chemical injuries that can contribute to corneal damage. Soon the advances of this system will also breach the barriers surrounding corneal endothelial [91] and retinal pigment epithelial transplantation [92].

Scaffold-free tissue engineered cellular tools have advantages over many scaffolds currently available due to their high cellular availability and long term engraftment. This might be due to the non-invasive thermo-responsive cellular detachment method allowing cells to maintain its ECM, surface proteins, growth factors receptors, ion channel and junctional proteins, which are vital for cellular differentiation [93,94]. However, the disadvantages of cellular sheet approach are possibly the premature detachment of cells or insufficient contact of transplanted cells on the corneal surface. In addition, the costs of the system and the time involved in the manufacturing of

autologous cell sheets are part of the disadvantages. These methods need to be further refined to include protocols to assess tissue viability, the quality of tissue constructs and safety assessment. The quality of cells in the tissue construct is vital to ensure permanent tissue repair and successful engraftment.

Conclusion

There have been significant developments in tissue engineering-based therapeutic tools for the treatment of LSCD. *Ex vivo* expanded LSC transplantation has been proven to be able to reconstruct the ocular surface in LSCD eyes using a biological scaffold system which provides transfer of proliferative cells to the target site. The search for the ultimate construct has posed the clinicians, scientists and the industry with many challenges before it can be realized into human clinical trials and clinical practice. Future directions in this field should focus on the development of a high speed, consistent in quality, affordable cell propagation system, accredited by regulatory bodies, and accessible to many users.

References

1. Dua HS, Shanmuganathan VA, Powell-Richards AO, Tighe PJ, Joseph A. Limbal epithelial crypts: a novel anatomical structure and a putative limbal stem cell niche. *British Journal of Ophthalmology*. 2005; 89:n 529-532.
2. Shortt AJ, Secker GA, Munro PM, Khaw PT, Tuft SJ, Daniels JT. Characterization of the limbal epithelial stem cell niche: novel imaging techniques permit *in vivo* observation and targeted biopsy of limbal epithelial stem cells. *Stem Cells*. 2007; 25: 1402-1409.
3. Schlötzer-Schrehardt U, Kruse FE. Identification and characterization of limbal stem cells. *Exp Eye Res*. 2005; 81: 247-264.
4. Davanger M, Evensen A. Role of the pericorneal papillary structure in renewal of corneal epithelium. *Nature*. 1971; 229: 560-561.
5. Schermer A, Galvin S, Sun TT. Differentiation-related expression of a major 64K corneal keratin *in vivo* and in culture suggests limbal location of corneal epithelial stem cells. *The Journal of Cell Biology*. 1986; 103: 49-62.
6. Yeung AM, Schlötzer-Schrehardt U, Kulkarni B, Tint NL, Hopkinson A, Dua HS. Limbal epithelial crypt: a model for corneal epithelial maintenance and novel limbal regional variations. *Arch Ophthalmol*. 2008; 126: 665-669.
7. Sun TT, Tseng SC, Lavker RM. Location of corneal epithelial stem cells. *Nature*. 2010; 463: 10-11.
8. Di Girolamo N, Bobba S, Raviraj V, Delic NC, Slapetova I, Nicovich PR, et al. Tracing the fate of limbal epithelial progenitor cells in the murine cornea. *Stem Cells*. 2015; 33: 157-169.
9. Amitai-Lange A, Altshuler A, Bublej J, Dbayat N, Tiosano B, Shalom-Feuerstein R. Lineage tracing of stem and progenitor cells of the murine corneal epithelium. *Stem Cells*. 2015; 33: 230-239.
10. Ahmad S. Concise review: limbal stem cell deficiency, dysfunction, and distress. *Stem Cells Transl Med*. 2012; 1: 110-115.
11. He Y, Pan Z, Luo F. A novel PAX6 mutation in Chinese patients with severe congenital aniridia. *Curr Eye Res*. 2012; 37: 879-883.
12. Smith WM, Lange JM, Sturm AC, Tanner SM, Mauger TF. Familial peripheral keratopathy without PAX6 mutation. *Cornea*. 2012; 31: 130-133.
13. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. *Ophthalmology*. 1989; 96: 709-722.
14. Langer R, Vacanti JP. Tissue engineering. *Science*. 1993; 260: 920-926.
15. Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. *Lancet*. 1997; 349: 990-993.
16. Nakamura T, Sotozono C, Bentley AJ, Mano S, Inatomi T, Koizumi N, et

- al. Long-Term Phenotypic Study after Allogeneic Cultivated Corneal Limbal Epithelial Transplantation for Severe Ocular Surface Diseases. *Ophthalmology*. 2010; 117: 2247-2254.
17. Niethammer D, Kümmerle-Deschner J, Dannecker GE. Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: striking the balance. *Rheumatology (Oxford)*. 1999; 38: 747-750.
18. Daniels JT, Secker GA, Shortt AJ, Tuft SJ, Seetharaman S. Stem cell therapy delivery: treading the regulatory tightrope. *Regen Med*. 2006; 1: 715-719.
19. Magnus D. Translating stem cell research: challenges at the research frontier. *J Law Med Ethics*. 2010; 38: 267-276.
20. Daya SM, Watson A, Sharpe JR, Giledi O, Rowe A, Martin R, et al. Outcomes and DNA analysis of *ex vivo* expanded stem cell allograft for ocular surface reconstruction. *Ophthalmology*. 2005; 112: 470-477.
21. Shimazaki J, Kaido M, Shinozaki N, Shimmura S, Munkhbat B, Hagihara M, et al. Evidence of Long-term Survival of Donor-Derived Cells after Limbal Allograft Transplantation. *Investigative Ophthalmology & Visual Science*. 1999; 40: 1664-1668.
22. Djalilian AR, Mahesh SP, Koch CA, Nussenblatt RB, Shen D, Zhuang Z, et al. Survival of Donor Epithelial Cells after Limbal Stem Cell Transplantation. *Investigative Ophthalmology & Visual Science*. 2005; 46: 803-807.
23. Baylis O, Figueiredo F, Henein C, Lako M, Ahmad S. 13 years of cultured limbal epithelial cell therapy: a review of the outcomes. *J Cell Biochem*. 2011; 112: 993-1002.
24. Pellegrini G, Rama P, Matuska S, Lambiase A, Bonini S, Pocobelli A, et al. Biological parameters determining the clinical outcome of autologous cultures of limbal stem cells. *Regen Med*. 2013; 8: 553-567.
25. Shortt AJ, Secker GA, Notara MD, Limb GA, Khaw PT, Tuft SJ, et al. Transplantation of *Ex Vivo* Cultured Limbal Epithelial Stem Cells: A Review of Techniques and Clinical Results. *Survey of Ophthalmology*. 2007; 52: 483-502.
26. Zhao Y, Ma L. Systematic review and meta-analysis on transplantation of *ex vivo* cultivated limbal epithelial stem cell on amniotic membrane in limbal stem cell deficiency. *Cornea*. 2015; 34: 592-600.
27. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. *N Engl J Med*. 2010; 363: 147-155.
28. Meeson A, Fuller A, Breault DT, Owens WA, Richardson GD. Optimised protocols for the identification of the murine cardiac side population. *Stem Cell Rev*. 2013; 9: 731-739.
29. Shahrudin B, Harvey I, Ahmad S, Ali S, Meeson A. Characterisation of human limbal side population cells isolated using an optimised protocol from an immortalised epithelial cell line and primary limbal cultures. *Stem Cell Rev*. 2014; 10: 240-250.
30. Petersdorf EW. The major histocompatibility complex: a model for understanding graft-versus-host disease. *Blood*. 2013; 122: 1863-1872.
31. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 2011; 117: 3921-3928.
32. Fan H, Cao P, Game DS, Dazzi F, Liu Z, Jiang S. Regulatory T cell therapy for the induction of clinical organ transplantation tolerance. *Semin Immunol*. 2011; 23: 453-461.
33. Koizumi N, Fullwood NJ, Bairaktaris G, Inatomi T, Kinoshita S, Quantock AJ. Cultivation of Corneal Epithelial Cells on Intact and Denuded Human Amniotic Membrane. *Investigative Ophthalmology & Visual Science*. 2000; 41: 2506-2513.
34. Nakamura T, Inatomi T, Sotozono C, Amemiya T, Kanamura N, Kinoshita S. Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders. *Br J Ophthalmol*. 2004; 88: 1280-1284.
35. Kolli S, Ahmad S, Mudhar HS, Meeny A, Lako M, Figueiredo FC. Successful application of *ex vivo* expanded human autologous oral mucosal epithelium for the treatment of total bilateral limbal stem cell deficiency. *Stem Cells*. 2014; 32: 2135-2146.
36. Ma DH, Kuo MT, Tsai YJ, Chen HC, Chen XL, Wang SF, et al. Transplantation of cultivated oral mucosal epithelial cells for severe corneal burn. *Eye (Lond)*. 2009; 23: 1442-1450.
37. Satake Y, Higa K, Tsubota K, Shimazaki J. Long-term Outcome of Cultivated Oral Mucosal Epithelial Sheet Transplantation in Treatment of Total Limbal Stem Cell Deficiency. *Ophthalmology*. 2011; 118: 1524-1530.
38. Ahmad S, Stewart R, Yung S, Kolli S, Armstrong L, Stojkovic M, et al. Differentiation of human embryonic stem cells into corneal epithelial-like cells by *in vitro* replication of the corneal epithelial stem cell niche. *Stem Cells*. 2007; 25: 1145-1155.
39. Wang D, Quan Y, Yan Q, Morales JE, Wetsel RA. Targeted Disruption of the β 2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells. *Stem Cells Transl Med*. 2015; 4: 1234-1245.
40. Karabekian Z, Ding H, Gtybayeva G, Ivanova I, Muselimyan N, Toma I, et al. HLA class I depleted hESC as a source of hypoinmunogenic cells for tissue engineering applications. *Tissue Engineering Part A*. 2015.
41. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006; 126: 663-676.
42. Hayashi R, Ishikawa Y, Ito M, Kageyama T, Takashiba K, Fujioka T, et al. Generation of Corneal Epithelial Cells from Induced Pluripotent Stem Cells Derived from Human Dermal Fibroblast and Corneal Limbal Epithelium. *PLoS ONE*. 2012; 7: e45435.
43. Yu D, Chen M, Sun X, Ge J. Differentiation of mouse induced pluripotent stem cells into corneal epithelial-like cells. *Cell Biol Int*. 2013; 37: 87-94.
44. Hentze H, Soong PL, Wang ST, Phillips BW, Putti TC, Dunn NR. Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies. *Stem Cell Research*. 2009; 2: 198-210.
45. Cunningham JJ, Ulbright TM, Pera MF, Looijenga LH. Lessons from human teratomas to guide development of safe stem cell therapies. *Nat Biotechnol*. 2012; 30: 849-857.
46. Boyd AS, Rodrigues NP, Lui KO, Fu X, Xu Y. Concise review: Immune recognition of induced pluripotent stem cells. *Stem Cells*. 2012; 30: 797-803.
47. Barbero A, Ploegert S, Heberer M, Martin. Plasticity of clonal populations of dedifferentiated adult human articular chondrocytes. *Arthritis & Rheumatism*. 2003; 48: 1315-1325.
48. Holan V, Trosan P, Cejka C, Javorkova E, Zajicova A, Hermankova B, et al. A Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells and Limbal Epithelial Stem Cells for Ocular Surface Reconstruction. *Stem Cells Transl Med*. 2015; 4: 1052-1063.
49. Liu Q, Hu C-H, Zhou C-H, Cui X-X, Yang K, Deng C, et al. DKK1 rescues osteogenic differentiation of mesenchymal stem cells isolated from periodontal ligaments of patients with diabetes mellitus induced periodontitis. *Scientific Reports*. 2015; 5: 13142.
50. Santos JM, Camões SP, Filipe E, Cipriano M, Barcia RN, Filipe M, et al. Three-dimensional spheroid cell culture of umbilical cord tissue-derived mesenchymal stromal cells leads to enhanced paracrine induction of wound healing. *Stem Cell Research & Therapy*. 2015; 6: 90.
51. Gu S, Xing C, Han J, Tso MO, Hong J. Differentiation of rabbit bone marrow mesenchymal stem cells into corneal epithelial cells *in vivo* and *ex vivo*. *Mol Vis*. 2009; 15: 99-107.
52. Ke Y, Wu Y, Cui X, Liu X, Yu M, Yang C, et al. Polysaccharide hydrogel combined with mesenchymal stem cells promotes the healing of corneal alkali burn in rats. *PLoS One*. 2015; 10: e0119725.
53. Alio del Barrio JL, Chiesa M, Garagorri N, Garcia-Urquia N, Fernandez-Delgado J, Bataille L, et al. Acellular human corneal matrix sheets seeded with human adipose-derived mesenchymal stem cells integrate functionally in an experimental animal model. *Experimental Eye Research*. 2015; 132: 91-100.

54. Almaliotis D, Koliakos G, Papakonstantinou E, Komnenou A, Thomas A, Petrakis S, et al. Mesenchymal stem cells improve healing of the cornea after alkali injury. *Graefes's Archive for Clinical and Experimental Ophthalmology*. 2015; 253: 1121-1135.
55. Levis HJ, Massie I, Dziasko MA, Kaasi A, Daniels JT. Rapid tissue engineering of biomimetic human corneal limbal crypts with 3D niche architecture. *Biomaterials*. 2013; 34: 8860-8868.
56. Rama P, Bonini S, Lambiase A, Golisano O, Paterna P, De Luca M, et al. Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. *Transplantation*. 2001; 72: 1478-1485.
57. Cai K, Gierman TM, Hotta J, Stenland CJ, Lee DC, Pifat DY, et al. Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens. *BioDrugs*. 2005; 19: 79-96.
58. Han B, Schwab IR, Madsen TK, Isseroff RR. A fibrin-based bioengineered ocular surface with human corneal epithelial stem cells. *Cornea*. 2002; 21: 505-510.
59. Saw VP, Minassian D, Dart JK, Ramsay A, Henderson H, Poniatowski S, et al. Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group. *Br J Ophthalmol*. 2007; 91: 1042-1047.
60. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. *Cornea*. 2001; 20: 408-413.
61. Tseng SC. Amniotic membrane transplantation for ocular surface reconstruction. *Biosci Rep*. 2001; 21: 481-489.
62. Kim JC, Tseng SCG. The effects on inhibition of corneal neovascularization after human amniotic membrane transplantation in severely damaged rabbit corneas. *Korean J Ophthalmol*. 1995; 9: 32-46.
63. Tseng SCG, Li D-Q, Ma X. Suppression of transforming growth factor-beta isoforms, TGF- β receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. *Journal of Cellular Physiology*. 1999; 179: 325-335.
64. Darouiche RO. Treatment of infections associated with surgical implants. *N Engl J Med*. 2004; 350: 1422-1429.
65. Bobba S, Chow S, Watson S, Di Girolamo N. Clinical outcomes of xeno-free expansion and transplantation of autologous ocular surface epithelial stem cells via contact lens delivery: a prospective case series. *Stem Cell Res Ther*. 2015; 6: 23.
66. Wright B, Mi S, Connon CJ. Towards the use of hydrogels in the treatment of limbal stem cell deficiency. *Drug Discov Today*. 2013; 18: 79-86.
67. Hatami-Marbini H, Rahimi A. Interrelation of Hydration, Collagen Cross-Linking Treatment, and Biomechanical Properties of the Cornea. *Curr Eye Res*. 2015.
68. Abou Neel EA, Cheema U, Knowles JC, Brown RA, Nazhat SN. Use of multiple unconfined compression for control of collagen gel scaffold density and mechanical properties. *Soft Matter*. 2006; 2: 986-992.
69. Mi S, Khutoryanskiy VV, Jones RR, Zhu X, Hamley IW, Connon CJ. Photochemical cross-linking of plastically compressed collagen gel produces an optimal scaffold for corneal tissue engineering. *Journal of Biomedical Materials Research A*. 2011; 99: 1-8.
70. Levis HJ, Menzel-Severing J, Drake RAL, Daniels JT. Plastic Compressed Collagen Constructs for Ocular Cell Culture and Transplantation: A New and Improved Technique of Confined Fluid Loss. *Current Eye Research*. 2012; 1-12.
71. Wright B, De Bank PA, Luetchford KA, Acosta FR, Connon CJ. Oxidized alginate hydrogels as niche environments for corneal epithelial cells. *Journal of Biomedical Materials Research A*. 2014; 102: 3393-3400.
72. Hoffman AS. Hydrogels for biomedical applications. *Advanced Drug Delivery Reviews*. 2012; 64: 18-23.
73. Mudera V, Morgan M, Cheema U, Nazhat S, Brown R. Ultra-rapid engineered collagen constructs tested in an *in vivo* nursery site. *Journal of Tissue Engineering and Regenerative Medicine*. 2007; 1: 192-198.
74. Levis HJ, Brown RA, Daniels JT. Plastic compressed collagen as a biomimetic substrate for human limbal epithelial cell culture. *Biomaterials*. 2010; 31: 7726-7737.
75. Kureshi AK, Drake RA, Daniels JT. Challenges in the development of a reference standard and potency assay for the clinical production of RAFT tissue equivalents for the cornea. *Regen Med*. 2014; 9: 167-177.
76. James R, Toti US, Laurencin CT, Kumbar SG. Electrospun nanofibrous scaffolds for engineering soft connective tissues. *Methods Mol Biol*. 2011; 726: 243-258.
77. Sharma S, Mohanty S, Gupta D, Jassal M, Agrawal AK, Tandon R. Cellular response of limbal epithelial cells on electrospun poly-e-caprolactone nanofibrous scaffolds for ocular surface bioengineering: a preliminary *in vitro* study. *Molecular Vision*. 2011; 17: 2898-2910.
78. Zajicova A, Pokorna K, Lencova A, Krulova M, Svobodova E, Kubinova S, et al. Treatment of ocular surface injuries by limbal and mesenchymal stem cells growing on nanofiber scaffolds. *Cell Transplant*. 2010; 19: 1281-1290.
79. Liu J, Lawrence BD, Liu A, Schwab IR, Oliveira LA, Rosenblatt MI. Silk Fibroin as a Biomaterial Substrate for Corneal Epithelial Cell Sheet GenerationSF as a Biomaterial Substrate. *Investigative Ophthalmology & Visual Science*. 2012; 53: 4130-4138.
80. Bray LJ, George KA, Suzuki S, Chirila TV, Harkin DG. Fabrication of a corneal-limbal tissue substitute using silk fibroin. *Methods Mol Biol*. 2013; 1014: 165-178.
81. Reichl S, Borrelli M, Geerling G. Keratin films for ocular surface reconstruction. *Biomaterials*. 2011; 32: 3375-3386.
82. Lynch AP, Ahearne M. Strategies for developing decellularized corneal scaffolds. *Exp Eye Res*. 2013; 108: 42-47.
83. Gonzalez-Andrades M, Cardona JdC, Ionescu A, Campos A, Perez MDM, Alaminos M. Generation of bioengineered corneas with decellularized xenografts and human keratocytes. *Invest Ophthalmol Vis Sci*. 2011; 52: 215-222.
84. Hashimoto Y, Funamoto S, Sasaki S, Honda T, Hattori S, Nam K, et al. Preparation and characterization of decellularized cornea using high-hydrostatic pressurization for corneal tissue engineering. *Biomaterials*. 2010; 31: 3941-3948.
85. Nishida K, Yamato M, Hayashida Y, Watanabe K, Yamamoto K, Adachi E, et al. Corneal Reconstruction with Tissue-Engineered Cell Sheets Composed of Autologous Oral Mucosal Epithelium. *New England Journal of Medicine*. 2004; 351: 1187-1196.
86. Shimizu H, Ohashi K, Utoh R, Ise K, Gotoh M, Yamato M, et al. Bioengineering of a functional sheet of islet cells for the treatment of diabetes mellitus. *Biomaterials*. 2009; 30: 5943-5949.
87. Ohashi K, Tatsumi K, Tateno C, Kataoka M, Utoh R, Yoshizato K, et al. Liver tissue engineering utilizing hepatocytes propagated in mouse livers *in vivo*. *Cell Transplant*. 2012; 21: 429-436.
88. Haraguchi Y, Shimizu T, Matsuura K, Sekine H, Tanaka N, Tadakuma K, et al. Cell sheet technology for cardiac tissue engineering. *Methods Mol Biol*. 2014; 1181: 139-155.
89. Bardag-Gorce F, Oliva J, Wood A, Hoft R, Pan D, Thropay J, et al. Carrier-free Cultured Autologous Oral Mucosa Epithelial Cell Sheet (CAOMECS) for Corneal Epithelium Reconstruction: A Histological Study. *The Ocular Surface*. 2015; 13: 150-163.
90. Burillon C, Huot L, Justin V, Nataf S, Chapuis F, Decullier E, et al. Cultured Autologous Oral Mucosal Epithelial Cell Sheet (CAOMECS) Transplantation for the Treatment of Corneal Limbal Epithelial Stem Cell Deficiency. *Investigative Ophthalmology & Visual Science*. 2012; 53: 1325-1331.
91. Sumide T, Nishida K, Yamato M, Ide T, Hayashida Y, Watanabe K, et al. Functional human corneal endothelial cell sheets harvested from temperature-responsive culture surfaces. *FASEB J*. 2006; 20: 392-394.
92. Yaji N, Yamato M, Yang J, Okano T, Hori S. Transplantation of tissue-

- engineered retinal pigment epithelial cell sheets in a rabbit model. *Biomaterials*. 2009; 30: 797-803.
93. Kushida A, Yamato M, Konno C, Kikuchi A, Sakurai Y, Okano T. Decrease in culture temperature releases monolayer endothelial cell sheets together with deposited fibronectin matrix from temperature-responsive culture surfaces. *Journal of Biomedical Materials Research*. 1999; 45: 355-362.
94. Kushida A, Yamato M, Isoi Y, Kikuchi A, Okano T. A noninvasive transfer system for polarized renal tubule epithelial cell sheets using temperature-responsive culture dishes. *Eur Cell Mater*. 2005; 10: 23-30.